Functionalized triazines as potent HCV entry inhibitors

Mull, Eric; Sun, Li‐Qiang; Zhao, Qian; Eggers, Betsy J.; Pokornowski, Kevin A.; Zhai, Guangzhi; Rajamani, Ramkumar; Jenkins, Susan; Kramer, Melissa; Wang, Ying-Kai; Fang, Hua; Tenney, Daniel J.; Baldick, Carl J.; Cockett, Mark I.; Meanwell, Nicholas A.; Scola, Paul M.

doi:10.1016/j.bmcl.2016.12.038

Cited by 4 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mull and co‐workers in 2016, described the synthesis of a series of novel acyl‐sulfonamide derivatives ( 108 – 110 ) bearing triazine nucleus [87] . The synthesized compounds were screened as Hepatitis C Virus (HCV) entry inhibitors; some of the analogues displayed nano‐molar potencies.…”

Section: Pharmacologymentioning

confidence: 99%

Recent Advances on the s‐Triazine Scaffold with Emphasis on Synthesis, Structure‐Activity and Pharmacological Aspects: A Concise Review

et al. 2021

View full text Add to dashboard Cite

Triazine nuclei have occupied a propitious place in pharmaceutical chemistry due to their diverse biological behaviour. The marketed drugs such as Azacitidine, Melarsoprol, Altretamine and Almitrine display broad pharmacological activities like anti‐cancer, anti‐parasitic, anti‐inflammatory, Respiratory stimulant and many more. Literature studies reveal that the 2, 4, and 6 substitution on s‐triazine is important for varied biological activities. This diversity in pharmacological activities of triazine scaffold has fascinated the various researchers to further investigate its applications in the treatment of several diseases. This review is complementary to earlier reports and aims to review the work reported on various synthetic methods and biological activities of substituted s‐triazine derivatives from 2016 to 2020 with a list of patents. The enriched structure‐activity relationship may open the doors for further rational drug development of s‐triazine containing analogues as good clinical candidates.

show abstract

Section: Pharmacologymentioning

confidence: 99%

Recent Advances on the s‐Triazine Scaffold with Emphasis on Synthesis, Structure‐Activity and Pharmacological Aspects: A Concise Review

et al. 2021

View full text Add to dashboard Cite

show abstract

Synthetic and pharmacological developments in the hybrid s-triazine moiety: A review

Bareth,

Jain,

Kumawat

et al. 2024

Bioorganic Chemistry

View full text Add to dashboard Cite

Recent Advances in Biological Active Sulfonamide based Hybrid Compounds Part B: Two-Component Sulfonamide Hybrids

Ghomashi

Aghaei

et al. 2023

CMC

View full text Add to dashboard Cite

Sulfonamide compounds, also known as sulfa drugs, are a significant class of synthetic bacteriostatic antimicrobials and were the primary source of therapy against bacterial infections before the introduction of penicillin in 1941. Hybridization of sulfonamides with various pharmaceutically active heterocyclic moieties leads to sulfonamide hybrids with a wide variety of biological activities. Part B of this review presents the most recent advances in designing and developing more two-component sulfonamide hybrids containing triazole, thiadiazole, triazine, oxazole/ benzoxazole, isoxazole, oxadiazole, imidazole, benzimidazole, furan, benzofuran, thiophene, pyrrole, indazole, tetrazole, chromene/ chromone, pyridazine, quinoxaline, acridine, phthalazine, and xanthone between 2015 and 2020. We hope this review helps the scientific community in designing more useful sulfonamide hybrid drugs.

show abstract

Functionalized triazines as potent HCV entry inhibitors

Cited by 4 publications

References 25 publications

Recent Advances on the s‐Triazine Scaffold with Emphasis on Synthesis, Structure‐Activity and Pharmacological Aspects: A Concise Review

Recent Advances on the s‐Triazine Scaffold with Emphasis on Synthesis, Structure‐Activity and Pharmacological Aspects: A Concise Review

Synthetic and pharmacological developments in the hybrid s-triazine moiety: A review

Recent Advances in Biological Active Sulfonamide based Hybrid Compounds Part B: Two-Component Sulfonamide Hybrids

Contact Info

Product

Resources

About